About Peplin
Peplin is a Healthcare company based in Emeryville (United States) founded in 1999, and was acquired by LEO Pharma in September 2009. It operates as a topical gel for the treatment of actinic (solar) keratosis. Peplin has completed 1 acquisition, including Neosil. Its chief executive is Tom Wiggans. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its competitors include Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Peplin was founded in 1999 in Emeryville, United States, with operations centered on medical dermatology. The company develops and commercializes products such as ingenol mebutate gel, known as PEP005, sourced from Euphorbia peplus for actinic keratosis treatment. Patents for this compounds use in dermatology are held by Peplin. As of November 2009, it functions as a wholly owned subsidiary of Leo Pharma.
- Headquarters Emeryville, United States
- Stage Acquired
- SectorsHealthcare
- Website peplin.com
- Social LinkedIn
- Acquired by LEO Pharma (Sep 2009)
- Latest Funding Round$24M (USD), Post-IPO
Aug 2008
- InvestorsLEO Pharma
& 2 more
- Investments & Acquisitions
- Acquired byLEO Pharma
(Sep 2009)
Funding Insights of Peplin
- Total Rounds 2
- Last Round Post-IPO — $24M
- First Round $7.29M
(Dec 2005)
- Investors Count 2
All 2 funding rounds of Peplin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2008 | $24M | Post-IPO | – | – | |
| Dec 2005 | $7.29M | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Peplin
Peplin has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include LEO Pharma, Turmeric Acquisition Corp and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | – | mpmcapital.com | - | |
Developer of drugs for treating dermatology diseases | 1908 | leo-pharma.com | Copenhagen, Denmark |
Investor details for Peplin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Peplin
1 people are tracked at Peplin (1 in leadership).
| Name | Role | Group |
|---|---|---|
Tom Wiggans | CEO | Leadership |
Complete people profiles for Peplin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Peplin
Peplin has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Neosil.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Specialty dermatology pharmaceuticals were developed by US-based Neosil until acquisition. | neosil.com | Palo Alto, United States | 2003 | Jun 2008 | $6.7M |
Complete acquisition details for Peplin
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Peplin
5 dated milestones of Peplin across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Peplin is founded.
- Funding First funding round of $7.3M.
- Acquisition Acquires Neosil.
- Funding Latest funding round, Post-IPO, of $24.0M.
- Exit Acquired by LEO Pharma.
Competitors of Peplin
Peplin has 9 listed competitors in our database, 7 of them funded. They include Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | – | Small molecule therapeutics for inflammatory skin diseases are developed. | |
| sol-gel.com | 1998 | United States | $9M | – | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | |
| bauschhealth.com | 1960 | Laval, Canada | – | 808 | Therapeutics for multiple diseases including dermatology and neurology are developed. | |
| hugel.co.kr | 2001 | Chuncheon-si, South Korea | – | – | Therapeutics in aesthetics are developed, including botulinum toxin products. | |
| kythera.com | 2005 | Calabasas, United States | $144.82M | 113 | Prescription products for aesthetic medicine are developed and commercialized. | |
| sofregen.com | 2014 | Medford, United States | $17.8M | 8 | Silk-derived biomaterials are developed for soft tissue repair in surgery. | |
| pyramidbio.com | 2015 | Waltham, United States | $71.19M | 3 | Small molecules are developed for dermatology and oncology treatments. |
Detailed competitors of Peplin
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
10 companies that operate in the same segment as Peplin (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608.25 M | – | 197 | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Peplin
Peplin was founded in 1999 and raised its 1st funding round 6 years after it was founded.
Peplin is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Tom Wiggans is the current CEO of Peplin.
Peplin was founded in 1999 in Emeryville, United States, with operations centered on medical dermatology. The company develops and commercializes products such as ingenol mebutate gel, known as PEP005, sourced from Euphorbia peplus for actinic keratosis treatment. Patents for this compounds use in dermatology are held by Peplin. As of November 2009, it functions as a wholly owned subsidiary of Leo Pharma.
Peplin's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
Peplin has made 1 acquisition, including Neosil.
Peplin has 3 investors. Key investors include LEO Pharma, Turmeric Acquisition Corp, and NEA.
Yes. Peplin was acquired by LEO Pharma in September 2009.